The median non-prostate cancer survival is more than 10 years for men up to age 80 years who are selected and receive curative radiation treatment for prostate cancer

Radiation Oncology

Volumn 2, Issue 1, 2007, Pages

  Blood, Paul A ^a   Pickles, Tom ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANADA; HUMAN; LIFE EXPECTANCY; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; NEOPLASM; ONCOLOGY; PATIENT SELECTION; PROBABILITY; RADIOTHERAPY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRITISH COLUMBIA; HUMANS; LIFE EXPECTANCY; MALE; MARKOV CHAINS; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASMS; PATIENT SELECTION; RADIATION ONCOLOGY; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 34547206678     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-2-17     Document Type: Article

References (17)

1. Heidenreich A Aus G Abbou CC Bolla M Joniau S Matveev V Schmid HP Zattoni F European Association of Urology Guidelines on Prostate Cancer Urology EA http://www.uroweb.org/fileadmin/user_upload/Guidelines/ 07_Prostate_Cancer_2007.pdf
2. Statistics Canada Statistics Canada. Life Tables, Canada, Provinces and Territories. 2000 to 2002 Life Tables, Canada, Provinces and Territories 2000 to 2002 http://www.statcan.ca/english/freepub/84-537-XIE/tables.htm
3. Miller DC Gruber SB Hollenbeck BK Montie JE Wei JT Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate Cancer in the United States J Natl Cancer Inst 2006, 98(16):1134-1141 16912266
4. Band PR Gaudette LA Hill GB Holowaty EJ Huchcroft SA Johnston GM Illing EMM Mao Y Semenciw RM The making of the Canadian cancer registry: Cancer incidence in Canada and its regions, 1969 to 1988. Ottawa, Minister of Supply and Services 1993 Catalogue Number C52-42/1992
5. McBride ML Donaldson L Ascertainment and data collection for a cancer registry BC Med J 1987, 29:30-40
6. Lukka H Prostate cancer: Risk categories and role of hormones and radiotherapy Can J Urol 2002, 9 Suppl 1:26-29 12121592
7. Pepe MS Mori M Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993, 12(8): 737-751 10.1002/sim.4780120803 8516591
8. Satagopan JM Ben-Porat L Berwick M Robson M Kutler D Auerbach AD A note on competing risks in survival data analysis Br J Cancer 2004, 91(7 :1229-1235 10.1038/sj.bjc.6602102 15305188
9. Lu-Yao G Albertsen PC Stanford JL Stukel TA Walker-Corkery ES Barry MJ Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut Bmj 2002, 325(7367):740 128373 12364300 10.1136/ bmj.325.7367.740
10. National Comprehensive Cancer Network (NCCN) National Comprehensive Cancer Network Practice Guidelines in Oncology http://www.nccn.org/ professionals/physician_gls/PDF/prostate.pdf
11. Royal College of Radiologists Clinical Oncology Information Network & The British Association of Urological Surgeons Royal College of Radiologists Guidelines on the Management of Prostate Cancer http://www.rcr.ac.uk/docs/oncology/other/prostate.htm
12. Alibhai SM Naglie G Nam R Trachtenberg J Krahn MD Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol 2003, 21 (17):3318-3327 10.1200/JCO.2003.09.034 12947068
13. Post PN Hansen BE Kil PJ Janssen-Heijnen ML Coebergh JW The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: A population-based study BJU Int 2001, 87(9): 821-826 10.1046/j.1464-410x.2001.02189.x 11412219
14. Singh R O'Brien TS Comorbidity assessment in localized prostate cancer: a review of currently available techniques European Urology 2004, 46(1): 28-41; discussion 41 10.1016/j.eururo.2004.01.010 15183545
15. Hall WH Ramachandran R Narayan S Jani AB Vijayakumar S An electronic application for rapidly calculating Charlson comorbidity score BMC Cancer 2004, 4:94 545968 15610554 10.1186/1471-2407-4-94
16. Kastner C Armitage J Kimble A Rawal J Carter PG Venn S The Charlson comorbidity score: A superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting Prostate Cancer Prostatic Dis 9(3):270-4 2006, 9(3):270-274 10.1038/sj.pcan.4500889
17. Penson DF Albertsen PC Nelson PS Barry M Stanford JL Determining cause of death in prostate cancer: Are death certificates valid? J Natl Cancer Inst 93(23):1822-3 2001, 93(23):1822-1823 10.1093/jnci/93.23.1822